Alessandra Russo

Alessandra Russo

Auto-generated profile, based on publicly available information

Alessandra Russo

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, I-84084 Fisciano, Salerno, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
ASSUNTA GIORDANOASSUNTA GIORDANO
ASSUNTA GIORDANO
GFGiovanni Forte
Giovanni Forte
Stefania TerraccianoStefania Terracciano
Stefania Terracciano
ARAlessandra Russo
Alessandra Russo
MSMarina Sala
Marina Sala
Simone Di MiccoSimone Di Micco
Simone Di Micco
JMJD3 is a member of the KDM6 subfamily and catalyzes the demethylation of lysine 27 on histone H3 (H3K27). This protein was identified as a useful tool in understanding the role of epigenetics in inflammatory conditions and in cancer as well. Guided by a virtual fragment screening approach, we identified the benzoxazole scaffold as a new hit suitable for the development of tighter JMJD3 inhibitors. Compounds were synthesized by a microwave-assisted one-pot reaction under catalyst and solvent-free conditions. Among these, compound 8 presented the highest inhibitory activity (IC50 = 1.22 ± 0.22 μM) in accordance with molecular modeling calculations. Moreover, 8 induced the cycle arrest in S-phase on A375 melanoma cells.

11 June 2018 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
Stefania TerraccianoStefania Terracciano
Stefania Terracciano
Gianluigi LauroGianluigi Lauro
Gianluigi Lauro
ARAlessandra Russo
Alessandra Russo
MVMaria Carmela Vaccaro
Maria Carmela Vaccaro
Antonio VassalloAntonio Vassallo
Antonio Vassallo
Ines BrunoInes Bruno
Ines Bruno
BAG3 protein has emerged as a key regulator of important cellular processes and its expression is increased in some tumor types; however, despite its potential value for future chemotherapeutics, no selective BAG3 modulators have been yet reported. Here we report the 2,4-thiazolidinedione derivative 28 as the first BAG3 protein modulator.

25 August 2016 in RSC Advances
Verified
Journal Article
Closed access
PDF file
Stefania TerraccianoStefania Terracciano
Stefania Terracciano
AFA. Foglia
A. Foglia
MCMaria Chini
Maria Chini
MVM. C. Vaccaro
M. C. Vaccaro
ARA. Russo
A. Russo
Ines BrunoInes Bruno
Ines Bruno
The inhibition of the C-terminal domain of heat shock protein 90 (Hsp90) is emerging as a novel strategy for cancer therapy, therefore the identification of a new class of C-terminal inhibitors is strongly required, also in consideration that to date only nature-inspired molecules have been largely expanded. Our recent discovery of potent antiproliferative dihydropyrimidone based C-terminal Hsp90 inhibitor (1, IC50 = 50.8 ± 0.2 μM and 20.8 ± 0.3 μM in A375 and Jurkat cell lines, respectively) drove us to further explore this very promising pharmacophoric core. In this study, we identified a new set of DHPM-derivatives that exhibited antiproliferative activity against two cancer lines by their modulation of Hsp90 C-terminus without inducing the undesired heat shock response. Our results strongly outline the high sensitivity of the Biginelli scaffold to structural decorations allowing us to point out also that small variations can deeply influence biological activity.